ESTRO 2025 - Abstract Book

S1397

Clinical - Lung

ESTRO 2025

Conclusion: AZD1390 was escalated to dose level 3 (40mg once-daily on RT days). Based on the observed oesophageal toxicity, the independent Safety Review Committee decided to close Arm B early. Analysis of patient-reported outcomes, efficacy outcomes and oesophagus-derived cfDNA are ongoing. Other Arms have been successfully escalated to dose levels 2 (C+E) or 3 (A) with integration of consolidation durvalumab in 2 arms (C+E) and recruitment continues.

Keywords: Platform trial, lung radiotherapy, radiosensitiser

References: 1. Yang JT, Wen PY, Imber BS, Drappatz J, Jena R, Forst D et al. Safety and preliminary efficacy of AZD1390 + radiation therapy for glioblastoma. Int J Radiat Onc Biol Phys 2024;120(2):S119-S120. 2. Walls GM, Oughton JB, Chalmers AJ, Brown S, Collinson F, Forster MD et al. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clin Transl Radiat Oncol 2020:25:61-66. 3. Walker K, Hinsley S, Phillip R, Oughton JB, Murden G, Chalmers AJ, Faivre-Finn C et al. Implementation of the time-to-event continuous reassessment method design in a phase I platform trial testing novel radiotherapy-drug combinations—CONCORDE. JCO Precis Oncol 2022;6:e2200133.